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80 Long term effects of azithromycin maintenance treatment on lung
function in pediatric cystic ﬁbrosis patients chronically infected
with Pseudomonas aeruginosa
A. Schoutens1, E. Wilms2, R. Stellato3, C.K. van der Ent1, S. Terheggen1.
1Wilhelmina’s Childrens Hospital, Pulmonology, Utrecht, Netherlands; 2The
Hague Hospital Pharmacy, The Hague, Netherlands; 3Julius Center Biostatistics
UMC Utrecht, Utrecht, Netherlands
Objectives: To evaluate the long term effects of azithromycin on lung function and
compare these results to a non-pseudomonas colonized cohort.
Methods: We included 74 cystic ﬁbrosis patients, treated at the CF centre of the
University Medical Centre Utrecht, who were chronically infected with P. aeru-
ginosa and who started azithromycin maintenance treatment between 1998 and
2005. We analysed decline in forced expiratory volume in 1 second percentage of
predicted (FEV1%) before and after start of azithromycin treatment, using linear
mixed effects models. We also compared FEV1% decline in our study group with
a non-pseudomonas colonized cohort, not treated with azithromycin maintenance
therapy (n = 60).
Conclusion: Initiation of azithromycin therapy is associated with a temporary
improvement of lung function. After the ﬁrst year patients with P. aeruginosa and
azithromycin have lung function decline comparable to patients without P. aerugi-
nosa and azithromycin.
81 A UK survey of anti-staphylococcal antibiotic prophylaxis (ASAP)
for cystic ﬁbrosis patients
B.R. Waterhouse1, B.J. Stewart1, K.W. Southern2. 1University of Oxford, Medical
School, Oxford, United Kingdom; 2University of Liverpool, Department for
Women’s and Children’s Health, Liverpool, United Kingdom
Cystic ﬁbrosis (CF) patients are vulnerable to Staphylococcus aureus airway
infection. There is international debate about the use of long-term antistaphylococcal
antibiotic prophylaxis (ASAP). The aim of this study was to examine the use of
ASAP in UK CF units. An online questionnaire was used to collect data on drug
regimens, age range, complications, palatability, and issues of compliance.
Results: 173 centres were contacted and 133 (77%) responded, representing
approximately 8700 patients. 95/103 (92%) paediatric units and 15/30 (50%) of
adult units were using ASAP. 85 (89%) paediatric units used ﬂucloxacillin; 10
used a trimethoprim-based regimen. Of those using ﬂucloxacillin, 68 (80%) follow
the UK CF Trust dosing guidelines, with other units modifying the guidelines for
local needs. All adult units used ﬂucloxacillin. Age ranges were highly variable; in
paediatric units, 46% used ASAP from diagnosis to transition, 31% from diagnosis
to 2 years (with other practices reported). ASAP was well tolerated, with low
complication rates. Most paediatric units experienced no complications (71%), but
9% report gastrointestinal symptoms. 28% of respondents reported compliance
issues and 74% reported difﬁculty with palatability, many relating to preparation
brand.
Conclusion: Most paediatric and a signiﬁcant number of adult CF units in the UK
use ASAP, but there is considerable variation in practice. A deﬁnitive and pragmatic
RCT is needed to guide practice.
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Background: The role of prophylactic anti-staphylococcal antibiotics in CF is not
well deﬁned.
Objectives: To evaluate the effect of secondary prophylactic antibiotics in chronic
colonization by Sa in CF during the winter months.
Setting: A prospective, monocentric study conducted at Bordeaux University
Hospital.
Methods: Children chronically colonized with Sa for more than 6 months were
included. They received continuous oral antibiotics (cotrimoxazole, rifampicin,
oxacillin, pristinamicin, amoxicillin and clavulanic acid or minocycline) according
to the antibiogram, alternating every 10 days for 3 months. Clinical, bacteriological
(sputum or throat swabs) and LFT evaluation performed prior to and at the end the
treatment period.
Results: 32 children were included, median age 9.2 years [0.8–16.4]. We observed
a signiﬁcant decrease in Sa Colony Forming Unit (CFU) (7 [2−9]/5 [0−8], p = 0.02).
Sa was eradicated in 43% (12/28) of all cases, and in 100% (2/2) of meticillin-
resistant Sa (MRSA). No emergence of bacteriological resistance, new colonisation
by P. aeruginosa or other pathogens were noted. FEV1 increased after treatment
(89.5±20.3% vs 92.3±15.8%, p = 0.6), especially in patients with an initial FEV1
less than 90% (p< 0.01). No patient presented with a pulmonary exacerbation
during the study period. The antibiotics were well tolerated, with weight gain and
good appetite.
Conclusion: Secondary prophylactic antibiotics directed against Sa during winter
signiﬁcantly reduces sputum Sa density, and improves pulmonary symptoms and
function. MRSA was eradicated in 100% of cases.
83 Investigation of RND efﬂux pumps in clinical Prevotella species
isolated from CF patients
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Objectives: Anaerobic Prevotella species, detected in the CF lung, have demon-
strated resistance to several antibiotics. Other gram negative bacteria, such as
P. aeruginosa, possess efﬂux pumps of the Resistance Nodulation Division (RND)
family, which contribute to antibiotic resistance. However, for Prevotella species, no
such pumps have yet been described. Our Aim is to determine if clinical Prevotella
isolates possess RND efﬂux pumps which contribute to antibiotic resistance.
Methods: Available genomes were searched for the presence of RND efﬂux pumps.
Prevotella isolates from CF patients (57 isolates), non-CF patients (14), healthy
controls (10) and type strains (2) were screened for the presence of efﬂux pumps
by PCR.
Results: Homology searching revealed the presence of either 1 (P. denticola,
P. nigrescens) or 2 (P. melaninogenica, P. histicola, P. veroralis, P. salivae) RND
efﬂux pumps within Prevotella genomes. With the exception of 2 P. melaninogenica
isolates, all isolates contained at least one RND efﬂux pump in their genome.
Ongoing susceptibility testing (E-test) in the presence and absence of an efﬂux
pump inhibitor (Phe-Arg b-napthylamide 2HCl) has shown a decrease in tetracycline
MIC from 32mg/ml to 24mg/ml for one CF P. salivae isolate when pump activity
was blocked.
Conclusion: RND efﬂux pumps are present in Prevotella isolates from CF patients.
Further characterisation of these pumps is ongoing to determine their importance
with respect to antibiotic resistance in Prevotella.
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